表紙
市場調査レポート

世界の胃腸疾患治療薬市場:過敏性大腸症候群(IBS)や慢性便秘(CC)、潰瘍性大腸炎(UC)を標的とした新規薬剤による市場の活性化

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

発行 GBI Research 商品コード 253373
出版日 ページ情報 英文 171 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の胃腸疾患治療薬市場:過敏性大腸症候群(IBS)や慢性便秘(CC)、潰瘍性大腸炎(UC)を標的とした新規薬剤による市場の活性化 Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market
出版日: 2012年11月01日 ページ情報: 英文 171 Pages
概要

世界の胃腸疾患治療薬の市場では、特に過敏性大腸症候群(IBS)やクローン病、潰瘍性大腸炎(UC)、胃食道逆流性疾患(GERD)、消化性潰瘍(PUC)の分野で、人気の高かった医薬品のジェネリック版が市場に次々と投入されています。一方で、より高い効能を持つ新薬の研究開発・市場投入も着々と進められており、全体としてはジェネリック医薬品による市場縮小を補って、市場規模を安定化させています。また、生活上のストレスの増加や不健康な食習慣、高齢化の進展、社会的な認知度の増大などが、市場の成長を促しています。

当レポートでは、全世界の胃腸疾患治療法の市場について分析し、世界全体および主要国の市場構造と動向(過去・今後7年間の実績値と予測値)、主な適応症別の市場の詳細(疾患概要、市場規模、年間治療費、治療法の利用パターン、市場促進・抑制要因など)、開発中のパイプライン製品の情報、主要企業の市場シェアと概要、主な資本取引の動向(年度別・地域別・金額別の件数内訳と最新動向)などを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の特徴

  • 市場の予測
    • ブランド薬/ジェネリック医薬品の世界市場シェア
    • 年間治療費
    • 治療法の利用パターン
  • 市場促進・抑制要因

第4章 各地域の市場環境

  • 地域別の市場収益の分析
  • 米国(市場収益・年間治療費・利用パターン)
  • 欧州主要5カ国(市場収益・年間治療費・利用パターン)
  • 日本(市場収益・年間治療費・利用パターン)
  • インド(疫学、治験、促進・抑制要因)
  • オーストラリア(疫学、治験、促進・抑制要因)
  • 中国(疫学、治験、促進・抑制要因)

第5章 治療環境

  • 過敏性大腸症候群(IBS)治療薬:世界市場の予測
  • 過敏性大腸症候群(IBS)治療薬:市場促進・抑制要因
  • 便秘治療薬:世界市場の予測
  • 便秘治療薬:市場促進・抑制要因
  • クローン病治療薬:世界市場の予測
  • クローン病治療薬:市場促進・抑制要因
  • 潰瘍性大腸炎治療薬:世界市場の予測
  • 潰瘍性大腸炎治療薬:市場促進・抑制要因
  • 胃食道逆流性疾患(GERD)治療薬:世界市場の予測
  • 胃食道逆流性疾患(GERD)治療薬:市場促進・抑制要因
  • 消化性潰瘍治療薬:世界市場の予測
  • 消化性潰瘍治療薬:市場促進・抑制要因

第6章 パイプライン分析

  • サマリー
  • 研究開発パイプライン:フェーズ別
  • 研究開発パイプライン:適応症別
  • 過敏性大腸症候群(IBS):研究開発パイプライン
  • 便秘:研究開発パイプライン:研究開発パイプライン
  • クローン病:研究開発パイプライン
  • 潰瘍性大腸炎:研究開発パイプライン
  • 胃食道逆流性疾患(GERD):研究開発パイプライン
  • 消化性潰瘍治療薬:研究開発パイプライン
  • 有望なパイプライン分子
    • Linzess (linaclotide)
    • Xifaxan (rifaximin)
    • Relistor (methylnaltrexone)
    • Humira (adalimumab)
    • Uceris (budesonide)
    • Plecanatide
    • Vedolizumab (MLN0002)
    • Naloxegol (NKTR-118)
    • Simponi (golimumab)
    • Asimadoline
    • Traficet-EN (GSK-1605786)
    • Cobiprostone

第7章 競争環境

  • 市場シェア分析
  • 主要企業のプロファイル
    • AstraZeneca
    • 武田薬品工業
    • Johnson & Johnson
    • エーザイ
    • Abbott Laboratories
    • Shire
    • Salix Pharmaceuticals

第8章 戦略的な企業統合

  • 概要
  • 企業合併・買収(M&A)
    • 主な企業合併・買収(M&A)案件
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数
  • ライセンス契約
    • 主なライセンス契約案件
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数
  • 共同開発/共同販売取引
    • 主な共同開発/共同販売取引
    • 年度別の件数
    • 地域別の件数
    • 金額帯別の件数

9章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC241MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market", which provides insights into the gastrointestinal disorders therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. It provides in-depth analysis of the major diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

GBI Research's analysis shows that the gastrointestinal disorders therapeutics market is set to witness high generic competition in the forecast period, as major drugs used in the treatment of the aforementioned disorders are set to expire, resulting in declining revenues and allowing generics to enter the market. Nevertheless, the market will witness steady growth due to the anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS, constipation, Crohn's disease and UC remains a key market driver.

Scope

  • Data and analysis for the gastrointestinal disorders therapeutics markets in the leading geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy and Spain; Japan; and an overview of India, China and Australia
  • Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010 and forecast to 2018
  • Market data for the geographical and therapeutic landscapes, including size, share, annual cost of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis population and prescription population
  • Generic share in the global market and for each indication
  • Key drivers and restraints that have had a significant impact on the market
  • The competitive landscape of the global market, looking at key companies such as AstraZeneca, Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix
  • Key M&A activity and licensing agreements that took place between 2010 and 2012

Reasons to buy

  • Align product portfolios to the markets with high growth potential
  • Build effective strategies to launch pipeline products by identifying potential geographies
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
  • Develop key strategic initiatives by studying top competitors' key strategies
  • Device a more tailored country strategy by understanding the key drivers, barriers and market potential for each indication
  • Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms producing safer and more efficacious FIC molecules

Executive Summary

Researchers Bust a Gut to Improve Gastrointestinal Disorders Market

Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by healthcare experts GBI Research.

The new report* states that patients with disorders such as Irritable Bowel Syndrome (IBS), Crohn's disease, Ulcerative Colitis (UC), Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.

The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth.

The gastrointestinal disorders therapeutics market is set to experience strong generic competition during the forecast period, as several major branded drugs used in to treat gastrointestinal disorders are set to expire during 2011-2015, including Nexium (esomeprazole magnesium), Aciphex (rabeprazole sodium), Tysabri (natalizumab) and Humira (adalimumab). This will result in a decline in the Annual Cost of Treatment (ACT), from $291 in 2011 to $261 in 2018 at a negative Compound Annual Growth Rate (CAGR) of 1.5%, although the launch of novel biologics will stabilize this drop.

However the market is set to witness a steady growth from 2015 onwards due to the anticipated entry of innovative new drugs, as the industry shows strong R&D activity in IBS, constipation, Crohn's disease and UC with effective and novel drug molecules. There are approximately 269 ongoing clinical trials in the gastrointestinal disorders therapeutics market, with the main focus being on Crohn's disease and UC. 42% of all ongoing clinical trials are in Phase II and 22% are in the late stages (Phase III and NDA-filed). This robust pipeline increases the chance of getting new drugs to market and may represent better treatment options with fewer side effects.

The Irritable Bowel Syndrome (IBS) and constipation therapeutics markets were valued at $722m and $1.7 billion in 2011, and are expected to grow at CAGRs of 13.7% and 11.1% to $1.8 billion and $3.6 billion respectively in 2018. This high growth rate is attributed to the strong pipeline dominated by First-In-Class (FIC) molecules such as recently launched Linzess (linaclotide). Others include Plecanatide, Xifaxan (rifaximin), Asimadoline and Naloxegol (PEG-naloxol), most of which have demonstrated high safety and efficacy profiles in clinical trials. There is a significant level of unmet need associated with current treatment options for IBS and constipation, and if these new therapies can address them, they will be able to command a price premium, thus driving the market.

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

This report provides in-depth analysis of the major gastrointestinal diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). It gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Gastrointestinal Disorders Therapeutics Market. Introduction

  • 2.1. Overview

3. Global Gastrointestinal Disorders Therapeutics Market. Market Characterization

  • 3.1. Market Forecasts
    • 3.1.1. Branded and Generic Global Market Share
    • 3.1.2. Annual Cost of Treatment
    • 3.1.3. Treatment Usage Patterns
  • 3.2. Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market
    • 3.2.1. Market Drivers
    • 3.2.2. Market Restraints

4. Gastrointestinal Disorders Therapeutics Market. Geographical Landscape

  • 4.1. Revenue Analysis by Geography
  • 4.2. The US
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Treatment
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Top Five Countries of Europe
    • 4.3.1. Revenue
    • 4.3.2. Revenue by Country
    • 4.3.3. Annual Cost of Treatment
    • 4.3.4. Treatment Usage Patterns
  • 4.4. Japan
    • 4.4.1. Revenue
    • 4.4.2. Annual Cost of Treatment
    • 4.4.3. Treatment Usage Patterns
  • 4.5. Gastrointestinal Disorders Therapeutics Market India-Overview
    • 4.5.1. Epidemiology
    • 4.5.2. Clinical Trials
    • 4.5.3. Drivers and Restraints
  • 4.6. Gastrointestinal Disorders Therapeutics Market Australia-Overview
    • 4.6.1. Epidemiology
    • 4.6.2. Clinical Trials
    • 4.6.3. Drivers and Restraints
  • 4.7. Gastrointestinal Disorders Therapeutics Market China-Overview
    • 4.7.1. Epidemiology
    • 4.7.2. Clinical Trials
    • 4.7.3. Drivers and Restraints

5. Global Gastrointestinal Disorders Therapeutics Market. Therapeutic Landscape

  • 5.1. Global Irritable Bowel Syndrome Therapeutics Market Forecasts
    • 5.1.1. Introduction
    • 5.1.2. Treatment Flow Algorithm
    • 5.1.3. Revenue
    • 5.1.4. Revenue by Country
    • 5.1.5. Branded vs. Generic Market Share
    • 5.1.6. Annual Cost of Treatment
    • 5.1.7. Treatment Usage Patterns
  • 5.2. Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market
    • 5.2.1. Drivers for the Irritable Bowel Syndrome Therapeutics Market
    • 5.2.2. Restraints for the Irritable Bowel Syndrome Therapeutics Market
  • 5.3. Global Constipation Therapeutics Market Forecasts
    • 5.3.1. Introduction
    • 5.3.2. Treatment Flow Algorithm
    • 5.3.3. Revenue
    • 5.3.4. Revenue Analysis by Country
    • 5.3.5. Branded vs. Generic Market Share
    • 5.3.6. Annual Cost of Treatment
    • 5.3.7. Treatment Usage Patterns
  • 5.4. Drivers and Restraints for the Constipation Therapeutics Market
    • 5.4.1. Drivers for Constipation Therapeutics Market
    • 5.4.2. Restraints for Constipation Therapeutics Market
  • 5.5. Global Crohn's Disease Therapeutics Market Forecasts
    • 5.5.1. Introduction
    • 5.5.2. Treatment Flow Algorithm
    • 5.5.3. Revenue
    • 5.5.4. Revenue by Country
    • 5.5.5. Branded vs. Generic Market Share
    • 5.5.6. Annual Cost of Treatment
    • 5.5.7. Treatment Usage Patterns
  • 5.6. Drivers and Restraints for the Crohn's Disease Therapeutics Market
    • 5.6.1. Drivers for the Crohn's Disease Therapeutics Market
    • 5.6.2. Restraints for the Crohn's Disease Therapeutics Market
  • 5.7. Global Ulcerative Colitis Therapeutics Market Forecasts
    • 5.7.1. Introduction
    • 5.7.2. Treatment Flow Algorithm
    • 5.7.3. Revenue
    • 5.7.4. Revenue by Country
    • 5.7.5. Branded vs. Generic Market Share
    • 5.7.6. Annual Cost of Treatment
    • 5.7.7. Treatment Usage Patterns
  • 5.8. Drivers and Restraints for the Ulcerative Colitis Therapeutics Market
    • 5.8.1. Drivers for the Ulcerative Colitis Therapeutics Market
    • 5.8.2. Restraints for the Ulcerative Colitis Therapeutics Market
  • 5.9. Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts
    • 5.9.1. Introduction
    • 5.9.2. Treatment Flow Algorithm
    • 5.9.3. Revenue
    • 5.9.4. Revenue by Country
    • 5.9.5. Branded vs. Generic Market Share
    • 5.9.6. Annual Cost of Treatment
    • 5.9.7. Treatment Usage Patterns
  • 5.10. Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market
    • 5.10.1. Drivers for the Gastroesophageal Reflux Disease Therapeutics Market
    • 5.10.2. Restraints for the Gastroesophageal Reflux Disease Therapeutics Market
  • 5.11. Global Peptic Ulcer Disease Therapeutics Market Forecasts
    • 5.11.1. Introduction
    • 5.11.2. Treatment Flow Algorithm
    • 5.11.3. Revenue
    • 5.11.4. Revenue Analysis by Country
    • 5.11.5. Generic vs. Branded Market Share
    • 5.11.6. Annual Cost of Treatment
    • 5.11.7. Treatment Usage Patterns
  • 5.12. Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market
    • 5.12.1. Drivers for Peptic Ulcer Disease Therapeutics Market
    • 5.12.2. Restraints for Peptic Ulcer Disease Therapeutics Market

6. Global Gastrointestinal Disorders Therapeutics Market. Pipeline Analysis

  • 6.1. Summary
  • 6.2. Research and Development Pipeline by Phase
  • 6.3. Research and Development Pipeline by Indication
  • 6.4. Irritable Bowel Syndrome: Research and Development Pipeline
    • 6.4.1. Pipeline by Phase
  • 6.5. Constipation: Research and Development Pipeline
    • 6.5.1. Research and Development Pipeline by Phase
  • 6.6. Crohn's Disease: Research and Development Pipeline
    • 6.6.1. Research and Development Pipeline by Phase
  • 6.7. Ulcerative Colitis: Research and Development Pipeline
    • 6.7.1. Research and Development Pipeline by Phase
  • 6.8. Gastroesophageal Reflux Disease: Research and Development Pipeline
    • 6.8.1. Research and Development Pipeline by Phase
  • 6.9. Peptic Ulcer Disease: Research and Development Pipeline
    • 6.9.1. Research and Development Pipeline by Phase
  • 6.10. Promising Pipeline Molecules
    • 6.10.1. Linzess (linaclotide)
    • 6.10.2. Xifaxan (rifaximin)
    • 6.10.3. Relistor (methylnaltrexone)
    • 6.10.4. Humira (adalimumab)
    • 6.10.5. Uceris (budesonide)
    • 6.10.6. Plecanatide
    • 6.10.7. Vedolizumab (MLN0002)
    • 6.10.8. Naloxegol (NKTR-118)
    • 6.10.9. Simponi (golimumab)
    • 6.10.10. Asimadoline
    • 6.10.11. Traficet-EN (GSK-1605786)
    • 6.10.12. Cobiprostone

7. Global Gastrointestinal Disorders Therapeutics Market. Competitive Landscape

  • 7.1. Market Share Analysis
  • 7.2. Profiles of Major Companies
    • 7.2.1. AstraZeneca
    • 7.2.2. Takeda Pharmaceutical Company
    • 7.2.3. Johnson. Johnson
    • 7.2.4. Eisai Co., Ltd.
    • 7.2.5. Abbott Laboratories
    • 7.2.6. Shire
    • 7.2.7. Salix Pharmaceuticals

8. Global Gastrointestinal Disorders Therapeutics Market. Strategic Consolidations

  • 8.1. Overview
  • 8.2. Mergers and Acquisitions
    • 8.2.1. Major Mergers and Acquisitions Deals
    • 8.2.2. Segmentation by Geography
    • 8.2.3. Segmentation by Deal Value
    • 8.2.4. Segmentation by Year
  • 8.3. Licensing Deals
    • 8.3.1. Major Licensing Deals
    • 8.3.2. Segmentation by Geography
    • 8.3.3. Segmentation by Deal Value
    • 8.3.4. Segmentation by Year
  • 8.4. Co-development/Co-marketing Deals
    • 8.4.1. Major Co-development/Co-marketing Deals
    • 8.4.2. Segmentation by Geography
    • 8.4.3. Segmentation by Deal Value
    • 8.4.4. Segmentation by Year

9. Gastrointestinal Disorders Therapeutics Market. Appendix

  • 9.1. Abbreviations
  • 9.2. Market Definitions
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Secondary Research
    • 9.4.2. Primary Research
    • 9.4.3. Expert Panel Validation
    • 9.4.4. Section-wise Research Methodology
  • 9.5. Therapeutic Landscape
    • 9.5.2. Market Size by Geography
  • 9.6. Geographical Landscape
  • 9.7. Pipeline Analysis
  • 9.8. Competitive Landscape
  • 9.9. Strategic Consolidations
  • 9.10. Contact Us
  • 9.11. Disclaimer

List of Tables

  • Table 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004-2011
  • Table 2: Gastrointestinal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
  • Table 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 4: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 5: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004-2011
  • Table 6: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2011-2018
  • Table 7: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004-2011
  • Table 8: Gastrointestinal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018
  • Table 9: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2011
  • Table 10: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2011-2018
  • Table 11: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004-2011
  • Table 12: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2011-2018
  • Table 13: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011
  • Table 14: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecast, ($bn), 2011-2018
  • Table 15: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004-2011
  • Table 16: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($bn), 2011-2018
  • Table 17: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2011
  • Table 18: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011-2018
  • Table 19: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004-2011
  • Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2011-2018
  • Table 21: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004-2011
  • Table 22: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2011-2018
  • Table 23: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2011
  • Table 24: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2011-2018
  • Table 25: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004-2011
  • Table 26: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2011-2018
  • Table 27: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), India, 2011
  • Table 28: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, India, 2012
  • Table 29: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), Australia, 2011
  • Table 30: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, Australia, 2012
  • Table 31: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), China, 2011
  • Table 32: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, China, 2012
  • Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011-2018
  • Table 37: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 38: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 39: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011
  • Table 40: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018
  • Table 41: Constipation Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 42: Constipation Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 43: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 44: Constipation Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
  • Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 46: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 47: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011
  • Table 48: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018
  • Table 49: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 50: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 51: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 52: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
  • Table 53: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 54: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 55: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004-2011
  • Table 56: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2011-2018
  • Table 57: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 58: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 59: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 60: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011-2018
  • Table 61: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 62: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 63: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011
  • Table 64: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018
  • Table 65: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 66: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 67: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 68: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
  • Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 70: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 71: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011
  • Table 72: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018
  • Table 73: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004-2011
  • Table 74: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 75: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2011
  • Table 76: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011-2018
  • Table 77: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2011
  • Table 78: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011-2018
  • Table 79: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2011
  • Table 80: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011-2018
  • Table 81: Gastrointestinal Disorders Therapeutics Market, Global, NDA-filed Molecules, 2012
  • Table 82: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase III Molecules, 2012
  • Table 83: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase II Molecules, 2012
  • Table 84: Gastrointestinal Disorders Therapeutics Market, Global, Major M&A Deals, 2010-Mid 2012
  • Table 85: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010-Mid-2012
  • Table 86: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010-Mid-2012
  • Table 87: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010-Mid-2012
  • Table 88: Gastrointestinal Disorders Therapeutics Market, Global, Major Licensing Deals, 2010-Mid-2012
  • Table 89: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010-Mid-2012
  • Table 90: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value, 2010-Mid 2012
  • Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012
  • Table 92: Gastrointestinal Disorders Therapeutics Market, Global, Major Co-development/Co-Marketing Deals, 2010-Mid-2012
  • Table 93: Gastrointestinal Disorders Therapeutics Market, Global, Co-development/Marketing Deals by Geography, 2010-Mid-2012
  • Table 94: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value, 2010-Mid-2012
  • Table 95: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012

List of Figures

  • Figure 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004-2018
  • Figure 2: Gastrointestinal Disorders Therapeutics Market, Global, Branded and Generic Market Share (%), 2011
  • Figure 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 4: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004-2018
  • Figure 5: Gastrointestinal Disorders Therapeutics Market, Global, Market Drivers and Restraints
  • Figure 6: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004-2018
  • Figure 7: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018
  • Figure 8: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004-2018
  • Figure 9: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2018
  • Figure 10: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004-2018
  • Figure 11: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2018
  • Figure 12: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004-2018
  • Figure 13: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004-2018
  • Figure 14: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018
  • Figure 15: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004-2018
  • Figure 16: Irritable Bowel Syndrome Therapeutics Market, Global, Breakdown of Irritable Bowel Syndrome Subtypes(%), 2012
  • Figure 17: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for Irritable Bowel Syndrome
  • Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 19: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 20: Irritable Bowel Syndrome Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011
  • Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018
  • Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints
  • Figure 24: Constipation Therapeutics Market, Global, Treatment Flow Algorithm for Constipation
  • Figure 25: Constipation Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 26: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 27: Constipation Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011
  • Figure 28: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 29: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018
  • Figure 30: Constipation Therapeutics Market, Global, Market Drivers and Restraints
  • Figure 31: Crohn's Disease Therapeutics Market, Global, Treatment Flow Algorithm for Crohn's Disease
  • Figure 32: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 33: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 34: Crohn's Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011
  • Figure 35: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 36: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004-2018
  • Figure 37: Crohn's Disease Therapeutics Market, Global, Market Drivers and Restraints
  • Figure 38: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for Ulcerative Colitis
  • Figure 39: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 41: Ulcerative Colitis Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011
  • Figure 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018
  • Figure 44: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints
  • Figure 45: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Self and Primary-care Treatment
  • Figure 46: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Secondary-care Treatment
  • Figure 47: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 48: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 49: Gastroesophageal Reflux Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011
  • Figure 50: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 51: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018
  • Figure 52: Gastroesophageal Reflux Disease Therapeutics Market, Market Drivers and Restraints
  • Figure 53: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Flow Algorithm
  • Figure 54: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004-2018
  • Figure 55: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004-2018
  • Figure 56: Peptic Ulcer Disease Therapeutics Market, Global, Generic vs. Branded Market Share (%)
  • Figure 57: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018
  • Figure 58: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004-2018
  • Figure 59: Peptic Ulcer Disease Therapeutics Market, Market Drivers and Restraints
  • Figure 60: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Phase, (%), 2012
  • Figure 61: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Indication, (%), 2012
  • Figure 62: Gastrointestinal Disorders Therapeutics Market, Global, IBS Pipeline by Phase, (%), 2012
  • Figure 63: Gastrointestinal Disorders Therapeutics Market, Global, Constipation Pipeline by Phase, (%), 2012
  • Figure 64: Gastrointestinal Disorders Therapeutics Market, Global, Crohn's Disease Pipeline by Phase, (%), 2012
  • Figure 65: Gastrointestinal Disorders Therapeutics Market, Global, Ulcerative Colitis Pipeline by Phase, (%), 2012
  • Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%), 2012
  • Figure 67: Gastrointestinal Disorders Therapeutics Market, Global, Peptic Ulcer Disease Pipeline by Phase, (%), 2012
  • Figure 68: Gastrointestinal Disorders Therapeutics Market, Global, Market Share by Company, %, 2011
  • Figure 69: Gastrointestinal Disorders Therapeutics Market, AstraZeneca, SWOT Analysis
  • Figure 70: Gastrointestinal Disorders Therapeutics Market, Takeda Pharmaceutical Company, SWOT Analysis
  • Figure 71: Gastrointestinal Disorders Therapeutics Market, Johnson & Johnson, SWOT Analysis
  • Figure 72: Gastrointestinal Disorders Therapeutics Market, Eisai Company Limited, SWOT Analysis
  • Figure 73: Gastrointestinal Disorders Therapeutics Market, Abbott Laboratories, SWOT Analysis
  • Figure 74: Gastrointestinal Disorders Therapeutics Market, Shire, SWOT Analysis
  • Figure 75: Gastrointestinal Disorders Therapeutics Market, Salix Pharmaceuticals, SWOT Analysis
  • Figure 76: Gastrointestinal Disorders Therapeutics Market, Deals by Type, 2010-Mid-2012
  • Figure 77: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010-Mid-2012
  • Figure 78: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010-Mid-2012
  • Figure 79: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010-Mid-2012
  • Figure 80: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010-Mid-2012
  • Figure 81: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010-Mid-2012
  • Figure 82: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010-Mid-2012
  • Figure 83: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Geography, 2010-Mid-2012
  • Figure 84: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010-Mid-2012
  • Figure 85: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Year, 2010-Mid 2012
  • Figure 86: GBI Research Market Forecasting Model
Back to Top